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myocardial infarction after stent thrombosis in both groups.
Conclusion: The incidence of stent thrombosis in Asian races is relatively low (0.5 %
with DES and 0.6% with BMS of SAT, 0.18% increase per year with DES of late stent
thrombosis) at mean follow-up to 6 years. Particular attention will need to be directed
to this complication when the patients have bifurcation lesions or low ejection fraction.
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Background: The Global Risk Categorisation (GRC), a combination of the SYNTAX
score (SXscore) & additive EuroSCORE, is superior to the SXscore alone in predicting
clinical outcomes in patients with 3VD &/or LMS coronary disease undergoing PCI.
The GRC is investigated in the All-Comers “real-world” SYNTAX population.
Methods: The study population (n=3075) consisted of pre-specified powered
randomised LMS & 3VD cohorts (n=1800) & non-randomisable nested CABG
(n=649/1077 randomly selected patients) & PCI (n=198) registries. The primary (all-
cause-death) & secondary (MACCE) endpoints at 36-months were analysed in
pre-defined low (n=1156), intermediate (n=1098) & high (n=356) risk categories.
Results: Baseline characteristics demonstrated significantly more adverse co-morbidity
within the All-Comers PCI population & more complex anatomy within the All-
Comers CABG population. At 36-months, within the LMS & 3VD All-Comers PCI
cohorts, the GRC separated a low risk (GRClow) group from the higher risk (GRCint)
group, for death & MACCE. Within the All-Comers CABG population, significant
differences between GRCint-high only were evident for death & MACCE.
Comparative analyses, between CABG & PCI in the GRClow LMS cohort, revealed
no statistically significant differences in death (CABG: 5.3%, PCI: 2.7%, HR 0.51
[95% C.I. 0.18, 1.44], p=0.19) & MACCE (CABG: 18.0%, PCI: 18.5%, HR 1.02 [95%
C.I. 0.65, 1.60], p=0.94), contrary to the randomized findings. Within the GRClow
3VD population, comparability in death (CABG: 5.1%, PCI: 5.9%, HR 1.16 [95% C.I.
0.62, 2.17], p=0.65) and significantly more MACCE (CABG: 17.9%, PCI: 24.4%, HR
1.42 [95% C.I. 1.03, 1.96], p=0.031) with PCI were evident.
Proposed Algorithm
Conclusion: The identification of low Global Risk patients within the All-Comers
SYNTAX population, reflecting “real-life” contemporary practice, maintains its clinical
usefulness in risk stratifying patients.
TCT-212
Are Results from an All-Comers Registry Comparable with the Results from an
All-Comers Randomized Clinical Trial? Insights from 12-Month Results of the
e-BioMatrix PMS Registry
Philip Urban1, Imad Al-Haddad2, Jean Jacques Berland3, Franz Eberli4, Magdi El-
Omar5, Jean-Jacques Goy6, David Hildick-Smith7, David G Iosseliani8, Franz-Xaver
Kleber9, Keith Oldroyd10, Giovanni B Pedrazzini11, Marco Roffi12, Mariano Valdés13,
Stephan Windecker14
1La Tour Hospital, Meyrin-Geneva, Switzerland; 2Jordan Cardiovascular Center,
Amman, Jordan; 3Clinique Saint-Hilaire, Rouen, France; 4Triemli Spital, Zurich,
Switzerland; 5Royal Infirmary, Manchester, United Kingdom; 6Hôpitaux
Fribourgeois, Fribourg, Switzerland; 7Brighton and Sussex Hospital, Brighton,
United Kingdom; 8Moscow City Hospital, Moscow, Russian Federation; 9Klinikum
Ernst von Bergmann, Potsdam, Germany; 10Golden Jubilee National Hospital,
Glasgow, United Kingdom; 11Cardio Center Ticino, Lugano, Switzerland; 12HUG,
Geneva, Switzerland; 13Hospital Universitario Virgen de la Arrixaca, Murica, Spain;
14University of Bern, Bern, Switzerland
Background: The safety and effectiveness of Biolimus A9™-eluting stents (BES) has
been evaluated relative to sirolimus-eluting stents in the LEADERS all-comers RCT
and in several observational registries. We compared the 1-year results for the first
1102 patients in the e-BioMatrix registry with the 857 patients in the BES arm of
LEADERS and analysed how the different study designs impacted the results.
Methods: Both the e-BioMatrix PMS registry and the LEADERS RCT are all-comers,
“real world” studies, not limited by lesion length, number of treated lesions/vessels or
clinical indication (chronic stable angina vs. ACS). The baseline characteristics were
similar (ex. mean age: 64.1 vs. 64.6 (p=0.35), DM: 24% vs. 26% (p=0.32), ACS: 53%
vs. 55% (p=0.41), STEMI: 16% vs 19% (p=0.05)). LEADERS had higher proportions
of patients with prior PCI and prior MI (36% vs 25% (p<0.001) and 32% vs 21%
(p<0.001)). We compared the rates of cardiac death, MI, clinically-indicated TVR and
ARC-defined stent thrombosis at 12 months.
Results: The patients enrolled in the e-BioMatrix registry had similar rates of cardiac
death (1.7% vs 2.1%) and QW MI (0.5% vs 0.5%) compared to those in LEADERS,
but exhibited lower rates of all MI (2.5% vs. 5.8%, p<0.001), and a trend towards lower
clinically-indicated TVR (4.3% vs 5.8%, p=0.12) at 1 year. The 1-year MACE rates
were 6.7% and 10.6% for e-BioMatrix and LEADERS respectively (p<0.01). Although
e-BioMatrix showed a lower rate of early definite ST vs LEADERS (0.5% vs 1.6%,
p<0.05), the rates of late ST were similar (0.4% vs 0.4%).
Conclusion: The e-BioMatrix PMS registry confirms the good safety profile of BES
at 12 months. Even though LEADERS was an “all-comers” study, some of the adverse
event rates were lower in the e-BioMatrix registry, especially during the first 30 days,
consistent with a patient selection process and a per protocol analysis (vs. ITT in
LEADERS). This could be related to mandatory ECG and biomarker determinations
required post-procedure in LEADERS together with different MI definitions. A 25%
rate of protocol mandated angiographic FU may also contributed to higher rates of
peri-procedural MI and TVR. However, the near identical event rates beyond 30 days
for all components of MACE, suggest that under-reporting of events is unlikely to have
played a major role.
TCT-213
Increased Tissue Stress Leads to Increased Neointima Evaluated by Histology
and Computational Modeling
Chad Abunassar1, Alexander Sheehy1, Santosh Prabhu1, Fumiyuki Otsuka2, Frank D
Kolodgie2
1R&D, Abbott Vascular, Santa Clara, CA; 2CVPath, Inc, Gaithersburg, MD
Background: The biomechanical performance of stenting can be best understood
through a coupling of computational modeling with in vivo pathology evaluations. To
this end, finite element analysis (FEA) of stent-artery interaction can be used to
characterize vessel-specific stresses and their correlation to biologic response.
Methods: Two bare-metal stent designs differing in strut thickness were compared for
differences in vessel wall stress. FEA was used to simulate the deployment of both
stent models in a mock artery model. Acute and chronic stresses induced in the vessel
wall were determined and compared between stent models. Stents (n=4) were
implanted in a normal rabbit iliac artery at 1.3:1 stent:artery ratio. Twenty-eight days
following stenting, histomorphometric analysis was performed.
Results: Stresses were ~70% lower for thin versus thick stents. Overall, there was
increased neointimal area in the thick versus thin stents (0.86±0.07 vs 0.66±0.10
p=0.02). Though neointimal thickness above struts trended lower in thick struts
(0.02±0.00 vs 0.03±0.01, p=0.08), the change in neointimal thickness immediately
adjacent to struts was greater in thick struts (0.18±0.00 vs 0.11±0.01 p<0.01).
Neointimal thickness was similar between the two groups between struts (0.07±0.02
vs 0.03±0.01 p=0.67).
Table 1: FEA predicted principal stress (PS) and Von Mises stress (VM) at stent
crest locations.
Conclusion: Stent design impacts the stress induced in the vessel wall during and after
stent deployment. Von Mises and principal stresses are focused at stent strut contact
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locations, while further away principal stresses predominate. Increased neointimal
thickness seems to relate to increased von Mises stresses at the site of stent struts.
Evaluating induced tissue stresses with stent-artery interaction models may improve
future device designs.
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Background: The safety and effectiveness of XIENCE V® everolimus-eluting stents
(XIENCE V, Abbott Vascular, Santa Clara, CA) at 1 year (1Y) in real world clinical
settings have been demonstrated in XIENCE V USA trial with low rates of target lesion
revascularization (TLR), cardiac death, MI and stent thrombosis (ST). Data on whether
these results are maintained through longer follow-up have not yet been reported.
Methods: XIENCE V USA is a prospective, multicenter, single-arm, FDA required
condition of approval study designed to examine the safety and effectiveness of
XIENCE V in an all-inclusive, consecutively-enrolled population from real world
clinical settings. Clinical endpoint events, including ST, cardiac death, MI, and
revascularization were adjudicated by an independent Clinical Events Committee.
Results: A total of 4382 patients completed 2-year (2Y) follow up. Baseline
Characteristics and Clinical Outcomes through 2Y appear in the table below.
Baseline Characteristics and Clinical Outcomes through 2 Years
1ARC MI definition: elevation of troponin or CKMB > 3 URL for periprocedual
PCI, > 5 URL for periprocedual CABG, and > 1 URL for spontaneous MI                   
2WHO MI definition: QMI per ECG or elevation of CK ≥ 2 URL with elevated
CKMB in the absence of new pathological Q waves              
3TLF: composite of cardiac death, MI attributed to target vessel, and clinically-
indicated TLR
Conclusion: Low event rates observed at 1Y were maintained through 2Y. Of note,
despite the increased number of patients who discontinued DAPT by 2 Y, the ST rate
remained consistently low, and <1% at 2Y. These results demonstrate continued safety
and effectiveness of the XIENCE V in a highly complex, real world patient population
through 2Y.
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Background: The purpose of the STEALTH I trial was to assess the safety and efficacy
of the Biolimus A9™-eluting stent with a biodegradable polymer coating
(BioMatrix™), as compared to a bare metal control stent (S-Stent™). The purpose of
this presentation is to present the 5 year and final report of this study.
Methods: This is a prospective, randomized, double-blind study which enrolled
patients in 3 centers in Germany (2) and Brazil. A total of 120 patients were enrolled
and randomly allocated 2:1 to receive the BioMatrix stent (BES) or the S-Stent (BMS).
The primary endpoint was in-stent late loss at 6 months. Secondary endpoints include
MACE defined as a composite of death, myocardial infarction, and target lesion
revascularization at 30 days, 3, 6 months, 1 year and then yearly up to 5 years.
Angiographic follow-up (measured by QCA) was protocol mandated at 6 months.
IVUS was performed immediately post-procedure and at 6 months.
Results: The mean age for BES patients was 62.2 ±10 years, 60.0% were male; 26.6%
had a history of diabetes mellitus. The in-stent late loss at 6 months was 0.19 mm ±
0.39 mm for BES patients compared to 0.76 mm (± 0.45 mm) for BMS patients (
p<0.001). In-segment late loss was 0.09 ± 0.31 (BES) vs. 0.48 ± 0.43 (BMS), p<0.001.
Out to 5 years a MACE event occurred in 13 patients (18.1%) for BES compared to 4
patients (10.5%) treated with a BMS (p =0.41). There was 1 acute and one late stent
thrombosis (protocol-defined) in the BES group.
Conclusion: The BioMatrix stent demonstrated statistical superiority for both in-
segment and in-stent late loss at 6 months compared to the bare metal control stent.
This benefit was achieved without an increase in adverse safety outcomes assessed.
The long-term clinical results demonstrate that the BioMatrix stent maintains an
adequate safety profile equal with conventional bare metal stents.
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Background: Information is lacking regarding prasugrel use following TAXUS Liberte
stent implantation in routine clinical practice.
Methods: The TAXUS Liberte Post-Approval Study is a prospective, multicenter
registry that will examine 5-year clinical outcomes in patients with implanted TAXUS
Liberte stents with concomitant prasugrel therapy. Enrollment of approximately 4200
total patients at up to 100 sites is planned. Following an initial enrollment of 3600
planned “real world” patients, an additional 600 patients with restricted eligibility
criteria will be enrolled. Once stented, patients will be prescribed aspirin and prasugrel
(at 5 mg or 10 mg doses, as appropriate) for 12 months, followed by 1:1 randomization
to either continued prasugrel or placebo for an additional 18 months. This presentation
will evaluate the in-hospital experience of the “real-world” patient cohort. Where
appropriate, comparisons will be made to the TAXUS ARRIVE registry, which enrolled
7492 “real world” patients receiving the previous generation TAXUS Express-2 stent
between 2004 and 2005.
Results: Enrollment of approximately 3600 “real world” patients was completed in
March 2011 and data are currently being analyzed. The presentation will include: (1)
patient demographics and procedural characteristics, compared across the TAXUS
Liberte and TAXUS ARRIVE registries; (2) data regarding prasugrel dose and usage
rates, including drug switching, in the TAXUS Liberte registry; (3) in-hospital major
adverse cardiac events (MACE; defined as cardiac death, myocardial infarction, and
target vessel revascularization) and stent thrombosis in the TAXUS Liberte registry
compared to TAXUS ARRIVE; and (4) cerebrovascular event rates and bleeding
(defined per GUSTO criteria) in the TAXUS Liberte registry.
Conclusion: The TAXUS Liberte Post-Approval Study will be the first to assess
prasugrel use in “real world” patients receiving the TAXUS Liberté stent. This abstract
will present the initial experience of this study, including in-hospital MACE,
cerebrovascular events, and bleeding data.
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Background: The sirolimus-eluting stent (SES) has reduced the rate of restenosis
compared to use of the bare-metal stent for longer stented segments. The object of the
study was to examine the relationships of total stent length (TSL) per patient and per
lesion with target lesion revascularization (TLR) and stent thrombosis (ST) at 5 years.
Methods: The j-Cypher Registry includes consecutive patients receiving a SES in 37
centers in Japan. By February 2011, 5-year follow-up data were available for 10,773
patients and 17,040 lesions with exclusively SES implantation. The patients and lesions
were divided into four groups according to quartiles for TSL per patient or per lesion:
Q1: TSL-P 8-18 mm, N=2,819; Q2: TSL-P 19-28 mm, N=2,570; Q3: TSL-P 28-51
mm, N=2,929; Q4: TSL-P 52-293 mm, N=2,455; QA: TSL-L 8-18 mm, N=6,167; QB:
TSL-L 19-23 mm, N=4,040; QC: TSL-L 23-33 mm, N=2,790; QD: TSL-L 33-150 mm,
N=4,043.
Results: The 5-year TLR rates were 8.8% in Q1, 9.8% in Q2, 14.1% in Q3 and 22.2%
in Q4 (p<0.0001); and 8.4% in QA, 9.1% in QB, 10.8% in QC and 17.4% in QD
(p<0.0001). The 5-year definite/probable ST per patient rates were 1.24% in Q1, 1.28%
in Q2, 1.88% in Q3 and 2.32% in Q4 (p<0.023); and definite stent thrombosis per
lesion rates were 0.88% in QA, 0.79% in QB, 1.00% in QC and 1.41% in QD
(p=0.0228).
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